Moleculin Biotech’s Chief Science Officer Buys 44 Shares After RSU Conversion, Sparking Investor Buzz and Price Lift
Insider buying by Moleculin Biotech’s Chief Science Officer signals confidence in its skin‑cancer pipeline and potential upcoming liquidity events. Click to learn how this tiny trade could shape the stock’s next move.
4 minutes to read